Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office VANCOUVER, BC, June 10,...